LEVO-T 88 MCG TABLET
For 30 tablets
Pharmacies pay
$1.48 filed
30 × $0.04947 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$12.44 filed
30 × $0.41464 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
8.4× estimated
Medicare paid 8.4× what pharmacies pay.
Part D averages every strength and form sold under “Levo-T” / “Levothyroxine Sodium” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$6.70 estimated
$1.48 + $0.22 (15%) + $5.00 fee per fill = $6.70
This is a model, not a price any pharmacy quoted. Shipping is not included. For a pack this cheap, the $5.00 fee is most of the estimate. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
LEVO-T 88 MCG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory does not list its NDC as a package of its own, so OpenBill has no FDA names, dosage form or pharmacologic class for it.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 55466-0107-11.
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $1.48 for 30 tablets (30 × $0.04947 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The NDC
- 55466-0107-11 · not listed as a package in the FDA directory · $0.04947 per EA · eff. 2026-09-23 filed
What Medicare paid
Medicare Part D paid $12.44 for 30 tablets, at an average of $0.41464 per EA in 2024 (2024-01-01 to 2024-12-31) for “Levo-T” and “Levothyroxine Sodium”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 9,029 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for LEVO-T 88 MCG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Levo-T / Levothyroxine Sodium: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.